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Abstract
Background: Allergy has been an increasing problem in several parts of the world. Prenatal exposure to allergen
and microbial components may affect the development of allergies in childhood, as indicated by epidemiological
and experimental studies. We investigated the capacity for allergic sensitisation in offspring after induction of a
Th1- or a Th2-polarised immune response to the same allergen in mothers during pregnancy.
Results: During pregnancy, mice were immunised with ovalbumin (OVA) given with either one of the Th2-
adjuvants pertussis toxin (PT) or Al(OH)3 (aluminium hydroxide), or with the Th1 adjuvant CpG. Offspring were
immunised with OVA in Al(OH)3 as young adults. Serum and supernatants from ex vivo stimulated or non-
stimulated spleen cells from mothers and offspring were analysed for OVA-specific antibodies and cytokines,
respectively. Mothers immunised with OVA together with either Al(OH)3 or PT had increased levels of OVA-specific
IgE and IgG1 compared to naive mothers, whereas mothers immunised with OVA together with CpG had
increased levels of OVA-specific IgG2a compared to naive mothers. In general the highest levels of IL-5, IL-10, and
IFNg were observed in spleen cells from mothers immunised with PT and OVA. Upon immunisation, offspring from
mothers immunised with OVA and either PT or Al(OH)3 showed reduced levels of OVA-specific IgE and IgG1 and
increased levels of OVA-specific IgG2a antibodies compared to offspring from naive mothers. Maternal
immunisation with CpG and OVA did not affect antibody responses in offspring.
Conclusion: Allergic sensitisation in the offspring was affected by the type of adjuvant used for immunisation of
the mothers with the same allergen. Th2 polarisation of the immune response in the mothers was found to give
reduced IgE levels upon sensitisation of the offspring, whereas no reduction was achieved with Th1 polarisation in
the mothers.
Background
The prevalence of allergy has been increasing in wester-
nised countries, and allergic diseases represent a major
burden for the patients and the society. Together with
early childhood, the gestational period appears to be
important in relation to the immune system and the
development of allergy [1,2]. Allergen-specific immune
responses in cord blood mononuclear cells (CBMCs)
have been detected already at 22 weeks of gestation [1].
Reduced mitogen- and allergen-induced IFNg secretion
in CBMCs has been reported in children who subse-
quently developed allergy [3,4]. These findings suggest
foetal allergen priming. However, the responses
observed may be non-specific rather than an allergen-
specific [5]. Increased total cord blood IgE levels has
been reported in children who develop allergy later in
life [6,7]. If the immune system can be primed in utero
for development of allergy, prevention of allergic disease
should start before birth.
Previously, our group has found reduced allergic sensi-
tisation in mouse offspring after immunisation of
mothers during pregnancy with allergen together with
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the adjuvant Al(OH)3 (inducing predominantly a Th2-
type of immune response) [8]. A cross-regulation
between Th1 and Th2 cells, resulting in reciprocal inhi-
bition has been suggested as a cause for the dominance
of either a Th1- or a Th2 response to an antigen in an
individual. Allergy is primarily associated with a Th2-
type of immune response, while Th1-promoting factors
have been proposed to reduce the risk for developing
allergy [9]. In the mother-offspring mouse model, we
wanted to study if polarisation of the maternal immune
response towards a Th1 or a Th2 immune response
using microbial components as adjuvants would differ-
ently influence sensitisation in offspring. Mothers were
immunised with OVA given with either PT (Th2 adju-
vant) or CpG (Th1 adjuvant) during pregnancy. Mothers
immunised with the Th2-adjuvant Al(OH)3 and OVA
used in previous studies served as positive controls. Sen-
sitisation was studied in offspring after immunisation
with OVA and Al(OH)3 at 6 weeks and OVA alone at 8
weeks of age. Sera from mothers and offspring were
analysed for OVA-specific antibodies and spleen cells
were analysed for cytokine release (IL-5, IL-10 and
IFNg). The findings challenge common perceptions
regarding the role of Th1- and Th2-promoting environ-
mental factors during pregnancy in relation to allergy
development.
Methods
Mice
Female and male inbred NIH/OlaHsd mice (age 6 to 7
weeks at arrival from Harlan UK Ltd. (Oxon, England))
were housed on BeeKay bedding (B&K Universal AS,
Nittedal, Norway). NIH/OlaHsd mice have good breed-
ing properties, and are good antibody responders with a
mixed Th1-Th2 immune response. The mice were
housed in type III macrolon cages in Thorens maximiser
racks with standard Hepa filter (Thoren Caging system,
Hazleton, Pennsylvania, USA), females and males on
separate sides of the rack. The mice were exposed to a
12 h/12 h light/dark cycle at room temperature (20 ±
2 °C), and 40-60% relative humidity. Female mice were
given pelleted food RM3 for extra nutrition during preg-
nancy, while males and offspring were given RM1 from
SDS (Essex, England) and tap water ad libitum. To start
the oestrus cycle, female mice were given paper and
bedding from the males’ cages on days 15, 16 and 17
after arrival [10]. On day 18, one male was placed in
each cage with three females. The next three days the
female mice were checked for vaginal plugs, and plugged
mice were moved to separate cages. If the plugged
female turned out to be pregnant, the first day of preg-
nancy was considered to be the day after the plug was
observed.
The experiments were performed in conformity with
the laws and regulations for experiments with live ani-
mals in Norway, and they were approved by the Experi-
mental Animal Board under the Ministry of Agriculture
in Norway.
Reagents used in the immunisation protocol
For all immunisations ovalbumin ((OVA), chicken egg
albumin, Grade VII, Sigma, St Louis, USA) was dis-
solved in Hanks Balanced Salt Solution (HBSS, Gibco
BRL, Paisly, UK). When given with an adjuvant, the dis-
solved OVA was mixed with either aluminium hydro-
xide gel adjuvant (3% Al(OH)3, Brenntag Biosector,
Fredriksund, Denmark), pertussis toxin (bordetella per-
tussis, CalBiochem, Cat. no 516560, Nottingham, Eng-
land) or CpG 1826 (’5-TCC ATG ACG TTC CTG ACG
TT-2’; TIB Molbiol, Berlin, Germany). The doses used
for the different reagents are given in Table 1.
Experimental protocol for mothers
Plugged mice were randomised to groups to be given Al
(OH)3, PT, CpG, or to be naive mothers (10 mothers
per treatment group). The adjuvants were given mixed
with OVA (see Table 1 for immunisation protocol).
During pregnancy mice were immunised by subcuta-
neous injection (0.2 ml) on days 3 and 10 of pregnancy
(Table 1). Before immunisation on day 3 of pregnancy
(T0) and on day 10 after giving birth (T10), the mice
were bled from the lateral femoral vein into heparinised
capillary tubes after puncture of the vessel with a 21-G
needle [11]. After weaning of the offspring (3 weeks
after birth), blood was collected from the dams by heart
puncture under CO2 anaesthesia and the spleens were
excised.
Experimental protocol for offspring
Three weeks old, the offspring were weaned from the
mothers, marked by ear punching and separated by gen-
der. All offspring were bled at 6 weeks of age (T0), and
immunised intraperitoneally (0.2 ml) at 6 and 8 weeks
(Table 1). Two males and 2 females per mother (n =
160, 40 mice per category of mother) received OVA
with Al(OH)3 at 6 weeks and OVA alone at 8 weeks.
Nine weeks old (TT) the offspring were anaesthetised
with CO2 and bled by heart puncture. Spleens were col-
lected from 48 of the immunised offspring.
ELISA for detection of OVA specific IgE, IgG2a, and IgG1
The detection of OVA-specific IgE has previously been
described by Løvik et al. [12] and modified by Ormstad
et al. [13]. OVA- specific IgG2a- and IgG1 antibodies
were determined as described by Nygaard et al. [14,15].
However, the avidin-biotin-complex (ABC) - alkaline
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phosphatase (ALP) reagent from Dako became unavailable
during the period of serum analyses. Therefore, a new pro-
cedure for colour development in the IgE and IgG2a
assays was introduced. Poly-horseradish peroxidase (HRP)
streptavidin (Thermo Scientific, Cat. No N200, Diagen
AS) was diluted 1:40 000 in 4% BSA/PBS and 100 μl was
added to each well. After incubation for 1 hour at 21°C,
the plates were washed and 100 μl of TBM Stabilized
Chromogen (Cat. No SB02, Biosource, Invitrogen, Carls-
bad, CA, USA) solution was added to each well and incu-
bated for 15 minutes at room temperature. Thereafter 2 N
H2SO4 (50 μl/well) was added to stop the colour develop-
ment process. The serum used for standard curve genera-
tion in the modified IgE assay was replaced by mouse anti-
OVA IgE from Serotec (MCA 2259). The absorbance
(OD) was measured at 405 nm with the original colour
development (IgE and IgG2a) and 450 nm with the new
colour development (IgE, IgG2a, and IgG1) on a MRX
Microplate Reader (Dynatech laboratories, Chantilly, VA,
USA) connected to a PC using BioLinx software (Dyna-
tech Laboratories) for instrument operation and calcula-
tions. The antibody levels are expressed in arbitrary units
(AU)/ml, which was calculated from standard serum pool
for IgG1 and IgG2a, whereas IgE was defined by the stan-
dard mouse anti-OVA IgE from Serotec. The modified
IgG2a and IgE assays were used for analysis of sera from
mothers at time-points T0 and T10, while in the offspring
the modified IgG2a assay was used at time-point T0. For
all other analyses the original assays were used. The quan-
titative ranges for the IgE, IgG1, and IgG2a assays are
about 2, 3, and 4 logs, respectively. All samples at each
given time-point were analysed on the same day and with
the same version of the ELISA assay. The average coeffi-
cients of variation between ELISA plates analysed on the
same day for IgE, IgG1, and IgG2a were 7%, 6%, and 13%,
respectively. If samples were below or above the
quantitative detection limits of the assay, they were given a
fixed value just below or just above the quantitative detec-
tion limits, respectively.
Ex vivo quantification of spleen cell cytokine production
The spleen was removed and a single cell suspension
prepared as described previously by Vinje et al. [16].
The spleen cells were seeded on 24-well culture plates
(Coaster 3473, Incorporated, NY, USA) to a final con-
centration of 5 × 106 cells/ml. OVA was added to a
final concentration of 1 mg/ml OVA. The cells were
incubated at 37°C and 5% CO2 for 72 hours or 6 days in
medium alone, or with OVA for 6 days. Thereafter the
plates were centrifuged, and supernatants were collected
and stored at -80°C. The concentrations of IL-5, IFNg,
and IL-10 in cell culture supernatants were determined
by ELISA according to the protocols provided by the
manufacturer (Mouse Duo Set, R&D Systems, Inc, Min-
neapolis, USA). The culture supernatants were added to
duplicate wells and analysed undiluted, diluted 1:10, or
1:100 depending on the expected concentration of the
cytokines. The absorbance was measured at 450 nm
(with a reference filter for correction at 550 nm), as
described above.
Data analysis
For statistical analysis of responses in offspring, the
mothers were used as the experimental unit, since the
offspring from each mother are not independent. This
means that the average value from all the offspring from
each mother was used. A two-sided Kruskal Wallis test
with Dunn’s post hoc test versus one control group was
used for all comparisons. All analyses were performed
with GraphPad Prism 5.0. In the text and tables, group
medians are given with 25- and 75- percentiles in par-
entheses. P < 0.05 was considered statistical significant.
Table 1 Immunisation protocol and time points for collection of blood and spleens
Host Time-points Maternal treatment
PT mothers CpG mothers Al(OH)3 mothers Naive mothers
Mothers Day 3 of pregnancy. Blood samples (T0)
10 μg OVA +
0.5 μg PT
N = 10
10 μg OVA +
50 μg CpG
N = 10
10 μg OVA +
2 mg Al(OH)3
N = 10
Not immunised
N = 10
Day 10 of pregnancy 1 μg OVA 1 μg OVA +
5 μg CpG
1 μg OVA +
0.2 mg Al(OH)3
Not immunised
Day 10 after delivery Blood samples (T10)
3 weeks after delivery Exsanguinated (TT): serum and spleens collected
Offspring 6 weeks Blood samples (T0)
Immunised: 10 μg OVA + 2 mg Al(OH)3
N = 40 offspring per maternal treatment group
8 weeks 10 μg OVA
9 weeks Exsanguinated (TT): serum and spleen cells were collected
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Results
Antibody and cytokine responses in mothers immunized
with OVA and PT, CpG, or Al(OH)3
First, we examined whether the adjuvants used had
induced a Th1- or Th2-dominant immune response in
the mothers as intended. Blood samples were taken
from the mothers on day 3 of pregnancy (T0) to deter-
mine antibody levels before immunisation, at 10 days
after delivery (T10), and at the end of the lactation per-
iod (TT) (Table 1). As expected, no OVA-specific anti-
bodies were detected before pregnancy (data not
shown). At weaning (TT), significantly higher levels of
anti-OVA IgE and IgG1 were observed in Al(OH)3- and
PT- treated mothers as compared to naive mothers
(Figures 1A and 1B). In contrast, CpG immunised
mothers had significantly higher levels of anti-OVA
IgG2a antibodies but not IgE and IgG1 antibodies com-
pared to naive mothers (Figure 1C). A similar antibody-
pattern was seen at 10 days after delivery (Table 2).
Spleen cells from PT treated mothers secreted signifi-
cantly higher levels of IL-5, IL-10, and IFNg compared to
naive mothers, both in non-stimulated and OVA-stimu-
lated cultures (Figure 2). The cytokine response patterns
and the level of cytokines measured in non-stimulated
spleen cells after 72 hours and after 6 days were similar.
OVA-stimulated spleen cells from Al(OH)3-treated
mothers secreted significantly higher amounts of IL-5
and IL-10 than cells from naive mothers (Figure 2C and
2F), whereas OVA-stimulated cells from CpG-treated
mothers secreted higher amounts of IL-10 and IFNg
compared to naive mothers (Figure 2F and 2I).
Antibody levels in naive offspring
Blood samples were taken from offspring before immu-
nisation at six weeks. Higher levels of anti-OVA IgG1
antibodies were observed in non-immunised offspring
from Al(OH)3 and PT mothers compared to non-immu-
nised offspring from naive mothers (Figure 3A). Simi-
larly, anti-OVA IgG1 antibody levels in non-immunised
offspring from CpG mothers tended to be increased
(n.s, Figure 3A). No significant differences in anti-OVA
IgG2a antibody levels were observed between the groups
(Figure 3B). Anti-OVA IgE antibodies were not detect-
able in any group at 6 weeks in non-immunised
offspring.
Antibody and cytokine levels in offspring at 9 weeks
To explore possible effects of different adjuvants used
for immunisation of the mothers during pregnancy on
offspring sensitisation, we immunised offspring with
OVA together with Al(OH)3. Immunised offspring from
Al(OH)3- and PT-treated mothers had significantly
reduced levels of OVA-specific IgE and IgG1 and
Figure 1 Antibody responses in mothers at weaning. Mothers
were immunised with the allergen ovalbumin (OVA) together with
either Al(OH)3, PT, or CpG. Naïve mothers served as negative
controls. OVA-specific IgE (A) and IgG1 (B), and IgG2a (C) antibodies
were measured at weaning and the antibody concentrations are
measured in arbitrary units (AU/ml). The median values are
indicated by a line, * denotes a statistically significant difference
compared to the OVA group, p < 0.05.
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increased levels of OVA-specific IgG2a compared to
immunised offspring from naive mothers (Figure 4A, B,
and 4C). No significant differences in antibody levels
were observed in immunised offspring from CpG-trea-
ted mothers compared to immunised offspring from
naive mothers.
Spleen cells from immunised offspring of Al(OH)3-
and PT-treated mothers secreted significantly higher
levels of IFNg after stimulation with OVA compared to
immunised offspring from naive mothers (Figure 5I).
Additionally, OVA-simulated cells from immunised off-
spring from Al(OH)3-treated mothers had significantly
higher levels of IL-5 and IL-10 compared to immunised
offspring from naive mothers (Figure 5C and 5F). No
significant difference was observed in cytokines levels
(IFNg, IL-10, and IL-5) between immunised offspring
from CpG mothers compared to immunised offspring
from naive mothers (Figure 5).
Discussion
In the present study, we confirm and extend previous
findings [8] that the capacity for allergic sensitisation to
an allergen in young adult offspring can be down-regu-
lated by immunisation of mothers with the correspond-
ing allergen during pregnancy.
By using different microbial components, we aimed at
skewing the immune response in mothers towards a
Th1 and a Th2 immune response. Increased levels of
Th2-associated anti-OVA IgE and IgG1 antibodies were
found in PT mothers, whereas CpG mothers had higher
levels of Th1-associated anti-OVA IgG2a antibodies. In
general, spleen cells from PT mothers secreted increased
levels of all three cytokines measured (IL-5, IL-10,
IFNg), and it was not possible to determine a clear Th1/
Th2 pattern at the cytokine level. CpG mothers secreted
increased levels of IL-10 and IFNg. As anticipated, also
the known Th2-adjuvant Al(OH)3 induced significantly
higher levels of IgE and IgG1 suggesting a Th2 domi-
nance in the mothers. Taken together, the antibody and
cytokine data indicate that CpG immunised mothers
achieved predominantly a Th1 immune response,
whereas PT and Al(OH)3 mothers displayed a Th2-
dominated response as intended. However, the
distinction was more clear at the antibody than at the
cytokine level.
The strongest protection against allergic sensitisation
in offspring was found to be associated with a Th2-type
immune response in the mothers, rather than with a
Th1-type immune response. This finding was demon-
strated in two independent experiments (data from one
experiment is shown). Two different Th2-adjuvants, the
microbial compound PT and the mineral adjuvant Al
(OH)3, induced Th2-biased immune responses in the
mothers and strong reduction of OVA-specific IgE and
IgG1 responses in the offspring. The Th1-adjuvant,
CpG, gave only slight (not statistically significant) mod-
ulation of offspring immune responses with respect to
OVA-specific IgE levels. This finding obviously is
important in the perspective of adjuvant selection for
modulation of allergy development in similar models,
which was the purpose of the study. It may also be rele-
vant for the discussion of environmental factors (’natural
adjuvants’) and allergy development, including the
“hygiene hypothesis” [17,18]. However, we have only
used one Th1 adjuvant in our study and this limits the
generalization of our findings to all Th1 adjuvants.
With regard to communication between the immune
systems of mother and child, specific maternal IgG1
antibodies are known to be transferred through the pla-
centa and with milk and have been suggested to be
involved in the protective effect on allergy development
[19-21]. A protective effect by IgG antibodies may be
explained by binding of IgG to the Fcg RIIb receptor on
neonatal B cells, and subsequent cross-linking of the Fcg
RIIb and B cell receptors by antigen, which may lead to
inhibition of B cell responses. However, maternal speci-
fic IgG may also mask antigenic determinants, and IgG
coated antigen may be cleared and destroyed by phago-
cytosis. Since we found up-regulation of OVA-specific
IgG2a levels in offspring, there is no general inhibition
of B-cell responses or masking of OVA-antigens in our
model. In a study by Seeger et al. suppression of IgE
against PLA2 was efficient also after maternal injection
of monoclonal anti-PLA2 IgG1 antibodies [22]. The
authors argued that it was not likely that one monoclo-
nal anti-PLA2 IgG1 antibody could cover the whole
Table 2 OVA-specific antibody levels in mothers 10 days after delivery (during lactation period)
Al(OH)3 mothers PT Mothers CpG mothers Naive mothers
IgE 2150
(1673-2360)*
4094
(2261-4953)*
90
(90-90)
90
(90-90)
IgG1 2.5 × 108
(1.6 × 108-4.2 × 108)*
3.0 × 108
(2.4 × 108-4.4 × 108)*
4.2 × 107
(2.1 × 107-7.8 × 107)
2.0 × 106
(2.0 × 106-2.1 × 106)
IgG2a 1.9 × 105
(9.9 × 104-3.3 × 105)
2.1 × 105
(9.6 × 104-10 × 105)
1.5 × 106
(9.6 × 105-5.2 × 106)
2.6 × 105
(1.1 × 105-1.2 × 106)
Mothers were immunised during pregnancy with either OVA + Al(OH)3, OVA + pertussis toxin (PT), OVA + CpG, or were not unimmunised. OVA-specific antibody
levels are given as medians with 25- and 75-percentiles (AU/ml). * p < 0.05.
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range of antigenic determinants and that masking of
determinants therefore hardly could be the mechanism
for the IgE suppression.
A higher level of anti-OVA IgG1 was found in non-
immunised offspring from Al(OH)3 and PT mothers at
6 weeks compared to non-immunised offspring from
naive mothers. Anti-OVA IgG1 antibodies measured in
non-immunised offspring most likely represent maternal
OVA-specific IgG1 antibodies transferred transplacen-
tally and via milk. Previously, supposedly maternal IgG1
antibodies have been found in up to 12 week-old off-
spring [21]. However, theoretically, the antibodies in
Figure 2 Cytokine response in spleen cells from mothers three weeks after delivery. Effect of immunisation of mother with ovalbumin
(OVA) combined with either Al(OH)3, pertussis toxin, or CpG on cytokine secretion from spleen cells (at weaning three weeks after birth)
incubated without allergen for 72 hours and 6 days or stimulated with OVA for 6 days. Ten mothers per group were included. The
concentrations of IL-5 (A, B, C), IL-10 (D, E, F) and IFNg (G, H, I) are given in pg/ml and the median values are indicated by a line, * denotes a
statistically significant difference compared to the OVA group, p < 0.05.
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non-immunised offspring could also be produced by the
offspring as a result of maternal influence transplacen-
tally and/or via milk. It has been observed even in
humans that maternally transferred IgG to inhalant
allergens in cord blood was associated with a reduction
of allergen specific IgE and reduced development of
later atopic disease in the child [23]. However, it must
Figure 3 Antibody responses in non-immunised offspring at 6
weeks. The figure shows the antibody responses in offspring before
the start of immunisation. During pregnancy their mothers’ immune
response had been polarised towards either a Th1 response
((OVA) + CpG) or a Th2 response (OVA + Al(OH)3 or OVA + PT). The
antibody concentration for IgG1 (A) and IgG2a (B) are provided in
arbitrary units (AU/ml) and the median values are indicated by a
line. Forty offspring per group of mother were included; the circles
represent the average value of 4 offspring from the same mother, *
denotes a statistically significant difference compared to the OVA
group, p < 0.05. Figure 4 Antibody responses in 9 week-old immunised
offspring. Antibody responses in allergen immunised offspring after
polarisation of the mothers immune response towards either a Th1
response ((OVA) + CpG) or a Th2 response (OVA + Al(OH)3 or
OVA + PT) during pregnancy. Serum levels of OVA-specific IgE (A),
IgG1 (B), and IgG2a (C) antibody concentrations are provided in
arbitrary units (AU/ml). The median values are indicated by a line.
Forty offspring per group of mother were included; the circles
represent the average value of 4 offspring from the same mother, *
denotes a statistically significant difference compared to the OVA
group, p < 0.05.
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be remembered that the presence of allergen-specific
IgG1 in mouse offspring does not necessarily mean that
the IgG1 is the mediator of protection against sensitisa-
tion. Even if IgG1 transferred from mother should be
the primary “communication” mechanism from mother
to offspring, persistence of maternal IgG1 may be irrele-
vant in relation to protection against sensitisation. The
increased levels of IgG2a in offspring of immunized
mothers may, hypothetically, have been caused by fetal
priming for this isotype, with a concomitant
“suppressive priming” with regard to IgE and IgG1
responses. If this is the case, a next question will be the
role of cytokines e.g. IL-10 in this hypothetical process
of isotype selective positive and negative fetal priming.
Surprisingly, we observed a better protective effect
against sensitisation in offspring from mothers with Th2
immunity compared to Th1 immunity during preg-
nancy. This is in apparent contradiction to the common
perception that a Th1-stimulating environment will pre-
vent allergy development [24]. Protection against allergy
Figure 5 Secretion of cytokines from spleen cells from 9 week-old immunised offspring. Cytokine response in offspring from mothers
immunised with ovalbumin (OVA) combined with either Al(OH)3, pertussis toxin, or CpG. Spleen cells were incubated alone or in combination
with the allergen OVA and cytokine secretion were measured after 72 hours (unstimulated) and 6 days (unstimulated or stimulated with OVA).
Ten offspring per group of mother were included. The concentrations of IL-5 (A, B, C), IL-10 (D, E, F) and IFNg (G, H, I) are given in pg/ml and the
median values are indicated by a line, * denotes a statistically significant difference compared to the OVA group, p < 0.05.
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in offspring has also been reported after injection of
mothers with the Th1 cytokine IFNg during pregnancy
[25]. However, our data suggest that IFNg is not crucial
in our model, since spleen cells from the CpG mothers
had increased secretion of IFNg after OVA stimulation,
while offspring showed little reduction of IgE produc-
tion. Although we skewed the antibody response
towards either a Th1 or a Th2 response in mothers, we
cannot exclude that the effect in the offspring of mater-
nal allergen immunisation may be mediated by increased
Treg activity. This could explain the discrepancy
between the results found in our study and the results
of Matson et al. (2007), who observed that Th1 immu-
nity during pregnancy (induced by CFA containing
killed Mycobacterium tuberculosis) suppressed allergic
sensitisation in the offspring more effectively than an
Al(OH)3-induced Th2 immunity during pregnancy
[26]. Killed mycobacteria have been shown to induce
regulatory T cells [27]. Some studies have shown a
reduced Th2 response in the offspring after their
mothers have been immunised with a Th2 adjuvant
[28,29], whereas others have not [26,30]. The diverging
results could be explained by different experimental
designs [26], since Matson et al. found protective
effects when using Al(OH)3 in one of the two studies
published using Al(OH)3 [26,31]. A slightly different
immunisation protocol and dose was used in these two
studies [26,31]. This illustrates that the experimental
design of the study is of importance. Also timing and
route of exposure may be of relevance for a successful
protection. Furthermore, other studies have shown an
increased Th2 response in the offspring born from
allergic mothers [32]. Another problem with compar-
ing these studies directly is the use of different mouse
strains, however the protection observed in offspring
in our model has been demonstrated in different
mouse strains (unpublished data).
The protective effect observed in the offspring after
immunising the mothers during pregnancy is very inter-
esting and promising for future prevention of allergy.
However, generalisation from mouse to humans can not
be done for several reasons, for instance materno-foetal/
offspring transmission of IgG in humans and the mouse
is different, and human and mouse IgG subclasses do
not correspond with regard designations and function.
Conclusion
Different microbial adjuvants used for maternal immuni-
sation were found to differently affect sensitisation to
the same allergen in offspring. The two adjuvants con-
ferring a maternal Th2-type immune response were
associated with a stronger reduction of allergen-specific
IgE production in the offspring than the microbial com-
ponent giving a maternal Th1-type immune response to
the allergen. However, we do not know whether this is a
general principle, or whether it is dependent on the spe-
cific adjuvants and/or route of exposure employed.
Whether the effect is long-lasting and antigen specific
can not be answered by this study. However, the finding
that maternal immunisation can suppress sensitisation
in the offspring is robust, and the concept of allergy pre-
vention by maternal immunisation should be further
explored.
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